Business
Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting
Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and CNS-penetrant KRAS G12C inhibitor
About this update from Erasca, Inc.
[{"type":"text","content":"Posters will feature programs with best-in-class potential including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and CNS-penetrant KRAS G12C inhibitor ERAS-3490\nSAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present six poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. The abstracts are currently available on the AACR meeting website. The posters will be available online at Erasca.com/events/presentations following the presentations. Poster Presentation Details Abstract 2672: ERAS-007 is a selective ERK1/2 inhibitor with preclinical activity across RAS/MAPK pathway-driven CRC modelsDate/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ETSession: Experimental and Molecular Therapeutics; Signaling Pathway InhibitorsPresenter: Erin Lew, Sr. Principal Scientist, Biology at ErascaLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 15Abstract 2671: ERAS-601, a potent allosteric inhibitor of SHP2, demonstrates compelling single agent anti-tumor activity in RAS/MAPK-driven tumor modelsDate/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ETSession: Experimental and Molecular Therapeutics; Signaling Pathway InhibitorsPresenter: Leenus Martin, Associate Director, Biology at ErascaLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 14Abstract 2670: ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the efficacy of sotorasib/adagrasib and cetuximab in NSCLC, CRC, and HNSCC tumor modelsDate/Time: Tuesday, April 12, 2022, 9:00 AM - 12:30 PM ETSession: Experimental and Molecular Therapeutics; Signaling Pathway InhibitorsPresenter: Les Brail, Vice President, Clinical Development at ErascaLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25, Poster Board 13Abstract 3345: ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the activity of a FLT3 inhibitor, gilteritinib, in FLT3-mutated AML tumor modelsDate/Time: Tuesday, April 12, 2022, 1:30 PM – 5:00 P...